Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Abstract Text:

INTRODUCTION: Because of its restricted distribution in normal tissues and its high expression on tumors of neuroectodermal origin, GD2 ganglioside is an excellent target for active specific immunotherapy. However, GD2 usually elicits low-titered IgM and no IgG or cellular immune responses, limiting its usefulness as a vaccine for cancer patients. We have previously shown that anti-idiotypic monoclonal antibody mimics of GD2 can induce antigen-specific humoral and cellular immunity in mice, but inhibition of tumor growth by the mimics could not be detected. METHODS AND RESULTS: Here, we isolated two peptides from phage display peptide libraries by panning with GD2-specific mAb ME361. The peptides inhibited binding of the mAb to GD2. When coupled to keyhole limpet hemocyanin (KLH) or presented as multiantigenic peptides in QS21 adjuvant, the peptides induced in mice antibodies binding specifically to GD2 and delayed-type hypersensitive lymphocytes reactive specifically with GD2-positive D142.34 mouse melanoma cells. Induction of delayed-type hypersensitivity (DTH) reaction was dependent on CD4-positive lymphocytes. The immunity elicited by the peptides significantly inhibited growth of GD2-positive melanoma cells in mice. CONCLUSION: Our study suggests that immunization with peptides mimicking GD2 ganglioside inhibits tumor growth through antibody and/or CD4-positive T cell-mediated mechanisms. Cytolytic T lymphocytes most likely do not play a role. Our results provide the basis for structural analysis of carbohydrate mimicry by peptides.

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer immunology, immunotherapy : CII

VOLUME: 57

Page Numbers: 1079-89

Journal Abbreviation: Cancer Immunol. Immunother.

ISSN: 0340-7004

DAY: 21

MONTH: Jul

YEAR: 2008

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8605732

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

AFFILIATION: Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

Country: Germany

AGENCY: United States NCI

GRANT: CA 93372

ACRONYM: CA

MEDLINETA: Cancer Immunol Immunother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice Related Publications

• Adenovirus infection enhances killing of melanoma cells by a mitotoxin.
• An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
• CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1.
• Downregulation of CCN3 expression as a potential mechanism for melanoma progression.
• Dynamics of cell interactions and communications during melanoma development.
• Endothelial cells as targets for tumor therapy.
• Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
• Learning the ABCs of Melanoma-Initiating Cells.
• Life isn't flat: taking cancer biology to the next dimension.
• Melanoma and the tumor microenvironment.
• Melanoma stem cells: the dark seed of melanoma.
• Old disease, new culprit: tumor stem cells in cancer.
• Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.
• Salmonella typhimurium as a novel RNA interference vector for cancer gene therapy.
• Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.
• Targeting the stromal fibroblasts: a novel approach to melanoma therapy.
• The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis.
• The many faces of Notch signaling in skin-derived cells.
• Unraveling the mysteries of IGF-1 signaling in melanoma.
• [1st successful immunization of pancreas and colorectal carcinoma patients with CO17-1A-vaccine]
• [Not Available.]
• [POSTOPERATIVE EFFECTS OF CESAREAN SECTION.]
• [Stability of Teschen, HCC, ND and vaccinia viruses against 5 disinfectants]